William E. Seaman, MD

Princeton University, Princeton, New Jersey, A.B., 1964, English (cum laude)
Harvard University, Boston, Massachusetts, M.D., 1969, Medicine (cum laude)

• 1969-70
  Intern and resident, Massachusetts General Hospital, Boston, Ma
• 1971-74
  Fellow, Arthritis and Rheumatism Branch, NIAMDD, NIH, Bethesda, MD
• 1974
  Senior Resident in Medicine, Massachusetts General Hospital
• 1975
  Chief Resident in Medicine, Massachusetts General Hospital
• 1976
  Clinical Fellow in Rheumatology, Massachusetts General Hospital
• 1976-84
  Assistant Professor of Medicine, University of California San Francisco
• 1978-2002
  Staff Physician, San Francisco VA Medical Center
• 1981-1992
  Chief, Arthritis/Immunology Section, San Francisco VA Medical Center
• 1984-1988
  Associate Professor of Medicine and Microbiology, UCSF
• 1988-present
  Professor of Medicine and Microbiology/Immunology, UCSF
• 1992-1999
  Chief, Medical Service, San Francisco VA Medical Center
• 1999-present
  Program Director, Sandler Program for Asthma Research
• 1999-present
  Chief, Immunology Section, San Francisco VA Medical Center
• 2000-present
  Director, Laboratory for the Development of Signaling Assays, Alliance for Cellular Signaling

• Seaman WE, Talal N, Herzenberg LA, Ledbetter JA: Surface antigens on mouse killer cells: Use of monoclonal antibodies to inhibit or to enrich cytotoxic activity. J Immunol 129:982-986, 1981.
• Wofsy D, Kerger CE, Seaman WE: Monocytosis in the BXSB model for systemic lupus erythematosus. J Exp Med 159:629-634, 1984.
• Wofsy D, Seaman WE: Successful treatment of autoimmunity in NZB/NZW mice with monoclonal antibody to L3T4. J Exp Med 161:378-391, 1985.
• Wofsy D, Seaman WE: Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 138:3247-3253, 1987.
• Seaman WE, Eriksson E, Dobrow R, Imboden JB: Inositol trisphosphate is generated by a rat natural killer cell tumor in response to target cells or to cross-linked monoclonal antibody OX-34: possible signalling role for the OX-34 determinant during activation by target cells. Proc Natl Acad Sci USA 84:4239-4243, 1987.
• Carteron NL, Wofsy D, Seaman WE: Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells. J Immunol 140:713-716, 1988.
• Seaman WE, Niemi EC, Stark MR, Goldfien RD, Pollock AS, Imboden JB: Molecular cloning of gp42, a cell-surface molecule that is selectively induced on rat natural killer cells by interleukin-2: Glycolipid membrane anchoring and capacity for transmembrane signaling, J Exp Med. 173:251-260, 1991.
• Ryan JC, Niemi EC, Goldfien RD, Hiserodt JC, Seaman WE: NKR-P1, an activating molecule in RAT NK cells, stimulates phosphoinositide turnover and a rise in intracellular calcium. J Immunol 147:3244, 1991.
• Yokoyama WM, Ryan JC, Hunter JJ, Smith HMC, Stark M, Seaman WE: cDNA cloning of mouse NKR-P1 and genetic linkage with Ly-49: Identification of a natural killer gene complex on mouse chromosome VI. J Immunol 147:3229, 1991.
• Ryan JC, Turck J, Niemi EC, Yokoyama WM, Seaman WE: Molecular cloning of the NK1.1 antigen, a member of the NKR-P1 family of natural killer cell activation molecules. J Immunol. 149:1631-1635, 1992.
• Yokoyama WM, Seaman WE: The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: The NK Gene Complex. Ann Rev Immunol II 613-635, 1993.
• Daniels BF, Nakamura MC, Rosen S, Yokoyama W, Seaman WE: Ly-49, a receptor for H-2Dd, has a functional carbohydrate recognition domain. Immunity 1:785-792, 1994.
• Ryan JC, Niemi EC, Nakamura MC, Seaman WE: NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. J Exp Med 181:1911-1915, 1995.
• Nakamura MC, Niemi EC, Fisher MJ, Shultz LD, Seaman WE, Ryan J. Mouse Ly-49A interrupts early signaling events in NK cell cytotoxicity and functionally associates with the SHP-1 tyrosine phosphatase. J Exp Med 185:673, 1997.
• Nakamura, MC, Linnemeyer, PA, Niemi EC, Mason,L., Ortaldo JR, Ryan JC, Seaman WE: Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity. J Exp Med, 189:493-500, 1999.
• Seaman WE. Natural killer cells and natural killer T cells. Arthritis Rheum 43:1204-17, 2000.
• Nakamura MC, Hayashi S, Niemi EC, Ryan JC, Seaman, WE: Activating Ly-49D and inhibitory Ly-49A NK cell receptors demonstrate distinct requirements for interaction with H2-Dd. J Exp Med 7:192:447-54, 2000.
• Daws MR, Lanier LL, Seaman WE, Ryan JC: Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol 31:783-91, 2001.
• Chung DH, Seaman WE, Daws MR. Characterization of TREM-3, an activating receptor on mouse macrophages: definition of a family of single Ig domain receptors on mouse chromosome 17. Eur J Immunol 32:59-66, 2002.
• Gilman AG, Simon MI, Bourne HR, et al. Overview of the Alliance for Cellular Signaling. Nature 420:703-6, 2002.
• Daws MR, Sullam PM, Niemi EC, Chen TT, Seaman WE. Pattern recognition by TREM-2: binding of anionic ligands. J Immunol. 171:594-9, 2003.
• Chung DH, Humphrey MB, Nakamura MC, Ginzinger DG, Seaman WE, Daws MR. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation. J Immunol. 171:6541-8, 2003.
• Chen TT, Brown EJ, Huang EJ, Seaman WE. Expression and function of SIRP- on astrocytomas. Cancer Res. 64:117-27, 2004. Xhu X, Hart R, Chang MS, et al. Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands. J Immunol. In Press, 2004.